EP3592357A4 - METHOD OF TREATMENT OF CANCER - Google Patents

METHOD OF TREATMENT OF CANCER Download PDF

Info

Publication number
EP3592357A4
EP3592357A4 EP17899634.4A EP17899634A EP3592357A4 EP 3592357 A4 EP3592357 A4 EP 3592357A4 EP 17899634 A EP17899634 A EP 17899634A EP 3592357 A4 EP3592357 A4 EP 3592357A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17899634.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3592357A1 (en
Inventor
Antonio MOSCHETTA
Jesús Maria Bañales ASURMEDI
Luis Bujanda Fernandez De PIEROLA
Maria Jesus Perugorria MONTIEL
Oihane Erice AZPARREN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of EP3592357A1 publication Critical patent/EP3592357A1/en
Publication of EP3592357A4 publication Critical patent/EP3592357A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17899634.4A 2017-03-07 2017-09-21 METHOD OF TREATMENT OF CANCER Withdrawn EP3592357A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468259P 2017-03-07 2017-03-07
PCT/US2017/052663 WO2018164715A1 (en) 2017-03-07 2017-09-21 Methods of treating cancer

Publications (2)

Publication Number Publication Date
EP3592357A1 EP3592357A1 (en) 2020-01-15
EP3592357A4 true EP3592357A4 (en) 2021-01-13

Family

ID=63447943

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17899634.4A Withdrawn EP3592357A4 (en) 2017-03-07 2017-09-21 METHOD OF TREATMENT OF CANCER

Country Status (9)

Country Link
EP (1) EP3592357A4 (https=)
JP (1) JP7042836B2 (https=)
KR (1) KR20190122251A (https=)
CN (1) CN110430882A (https=)
AU (1) AU2017402623A1 (https=)
CA (1) CA3055308A1 (https=)
IL (1) IL269123A (https=)
TW (1) TW201832768A (https=)
WO (1) WO2018164715A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022011037A2 (en) * 2020-07-07 2022-01-13 The General Hospital Corporation Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation
WO2023043375A2 (en) * 2021-09-16 2023-03-23 Agency For Science, Technology And Research Modulation of tjp1 expression to treat liver diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037482A1 (en) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US20140148428A1 (en) * 2012-11-28 2014-05-29 Intercept Pharmaceuticals, Inc. Treatment of Pulmonary Disease
WO2016176208A1 (en) * 2015-04-27 2016-11-03 Intercept Pharmaceuticals, Inc. Compositions of obeticholic acid and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107475A1 (en) * 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
US7932244B2 (en) 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
US10166246B2 (en) * 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
US11578097B2 (en) * 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037482A1 (en) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US20140148428A1 (en) * 2012-11-28 2014-05-29 Intercept Pharmaceuticals, Inc. Treatment of Pulmonary Disease
WO2016176208A1 (en) * 2015-04-27 2016-11-03 Intercept Pharmaceuticals, Inc. Compositions of obeticholic acid and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018164715A1 *

Also Published As

Publication number Publication date
WO2018164715A1 (en) 2018-09-13
KR20190122251A (ko) 2019-10-29
TW201832768A (zh) 2018-09-16
EP3592357A1 (en) 2020-01-15
CN110430882A (zh) 2019-11-08
JP2020510009A (ja) 2020-04-02
JP7042836B2 (ja) 2022-03-28
AU2017402623A1 (en) 2019-09-26
CA3055308A1 (en) 2018-09-13
IL269123A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
EP3630089A4 (en) PROCEDURE FOR CANCER THERAPY
EP3393475A4 (en) METHODS OF TREATING CANCER
EP3641770A4 (en) CANCER TREATMENT METHODS
EP3548028A4 (en) CANCER TREATMENT
EP3703669A4 (en) CANCER TREATMENT METHODS
AU2017246547A1 (en) Methods of treating pediatric cancers
IL262342A (en) Cancer treatment methods
EP3781215A4 (en) Methods of treating cancer
EP3119390A4 (en) Methods of treating cancer
ZA201908539B (en) Method of treatment of cancer
SG11202010793UA (en) Methods of treating cancer
EP3548007A4 (en) METHOD OF TREATMENT OF CANCER
IL281600B2 (en) Cancer treatment methods
EP3522887A4 (en) METHODS OF TREATING BILARIAN CANCER
EP3487999A4 (en) METHODS OF TREATING CANCER
EP3491129A4 (en) METHODS OF TREATING OSMIDROSIS
EP3200801A4 (en) Methods of treating pancreatic cancer
SG11202005163PA (en) Methods of treating cancer
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
IL269123A (en) Methods of treating cancer
HK40032563A (en) Methods of treating cancer
HK40016485A (en) Methods of treating cancer
HK40060332A (en) Methods of treating cancer
HK40059618A (en) Methods of treating cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191003

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAV Requested validation state of the european patent: fee paid

Extension state: MD

Effective date: 20191003

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031560000

Ipc: A61K0031575000

A4 Supplementary search report drawn up and despatched

Effective date: 20201214

RIC1 Information provided on ipc code assigned before grant

Ipc: C07J 1/00 20060101ALI20201208BHEP

Ipc: A61P 35/00 20060101ALI20201208BHEP

Ipc: A61K 31/575 20060101AFI20201208BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INTERCEPT PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230328

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230525

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230714